Blog Financial Times: Get vaccine new variant ready January 13, 2021 GreenLight Biosciences explain to the Financial Times how messenger RNA can help get the Covid-19 vaccine new variant ready. GreenLight Biosciences spoke to the Financial Times about making sure that any vaccine is new variant ready for Covid-19. An extract from the article is below: Andrey Zarur, chief executive of Greenlight Biosciences, a biotech company that is making a messenger RNA vaccine, said it made sense to design new vaccines to “prepare for further drift”.“Then you have a better chance of your new vaccine continuing to protect against new variants,” Mr Zarur said. Read the full article here. Find out more about how GreenLight manufactures RNA here. More of Greenlight Bioscience in the news: STAT: Businesses across the vaccine supply chain must work together to make Covid-19 vaccines Financial Times: Get vaccine new variant ready Mail Online: Vaccine roll out issues Financial Times: Vaccine makers race to fix vaccine supply issues Technology Review: What are the Pfizer covid-19 vaccine ingredients? Financial Times: Vaccine manufacturing delays leave UK with fewer vaccines than hoped